PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
-10%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.45%
AUM
$4.14B
AUM Growth
+$4.14B
(-27%)
Cap. Flow
-$722M
Cap. Flow
% of AUM
-17.44%
Top 10 Holdings %
Top 10 Hldgs %
47.31%
Holding
128
New
20
Increased
20
Reduced
31
Closed
18
Top Buys
| 1 |
Iovance Biotherapeutics
IOVA
|
$53.4M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$45.3M |
| 3 |
Immatics
IMTX
|
$40.7M |
| 4 |
CTNM
Contineum Therapeutics
CTNM
|
$27.6M |
| 5 |
Merus
MRUS
|
$17.8M |
Top Sells
| 1 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$149M |
| 2 |
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
$146M |
| 3 |
Medtronic
MDT
|
$73.9M |
| 4 |
Sarepta Therapeutics
SRPT
|
$68.1M |
| 5 |
Axsome Therapeutics
AXSM
|
$52M |
Sector Composition
| 1 | Healthcare | 99.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Xenon Pharmaceuticals
XENE
$2.98B
| $22.7M | 0.55% | 583,256 -308,952 | -35% | -$12M |
|
52
Ocular Therapeutix
OCUL
$2.12B
| $22.7M | 0.55% | 3,324,468 | – | – |
|
53
PepGen
PEPG
$38M
| $22.5M | 0.54% | 1,410,438 | – | – |
|
54
Viridian Therapeutics
VRDN
$1.5B
| $21.2M | 0.51% | 1,631,828 -2,025,271 | -55% | -$26.3M |
|
55
Orchestra BioMed
OBIO
$147M
| $20.7M | 0.5% | 2,545,881 | – | – |
|
|
56
Merus
MRUS
$4.98B
| $17.8M | 0.43% | +300,000 | New | +$17.8M |
|
|
RAPP
57
Rapport Therapeutics
RAPP
$643M
| $17.4M | 0.42% | +748,183 | New | +$17.4M |
|
58
Tyra Biosciences
TYRA
$675M
| $16.1M | 0.39% | 1,007,367 +338,208 | +51% | +$5.41M |
|
59
Inhibrx
INBX
$408M
| $15.1M | 0.36% | +1,064,026 | New | +$15.1M |
|
60
Arcutis Biotherapeutics
ARQT
$1.86B
| $14.5M | 0.35% | 1,558,500 +808,500 | +108% | +$7.52M |
|
61
Athira Pharma
ATHA
$15.3M
| $14.3M | 0.34% | 5,402,964 | – | – |
|
62
Zymeworks
ZYME
$1.12B
| $14.2M | 0.34% | 1,667,711 +592,904 | +55% | +$5.05M |
|
63
Cullinan Oncology
CGEM
$445M
| $13.1M | 0.32% | +749,916 | New | +$13.1M |
|
64
Procept Biorobotics
PRCT
$2.23B
| $12.9M | 0.31% | 210,659 | – | – |
|
65
Insmed
INSM
$28.8B
| $12.1M | 0.29% | +180,000 | New | +$12.1M |
|
|
BCYC
66
Bicycle Therapeutics
BCYC
$511M
| $11.6M | 0.28% | +572,000 | New | +$11.6M |
|
67
Icon
ICLR
$13.8B
| $9.8M | 0.24% | +31,250 | New | +$9.8M |
|
|
TEM
68
Tempus AI, Inc. Class A Common Stock
TEM
$13.2B
| $9.63M | 0.23% | +275,000 | New | +$9.63M |
|
69
ArriVent BioPharma
AVBP
$776M
| $7.7M | 0.19% | 415,000 | – | – |
|
70
enGene Holdings
ENGN
$236M
| $7.54M | 0.18% | 800,000 -198,888 | -20% | -$1.88M |
|
71
ARS Pharmaceuticals
SPRY
$1.15B
| $7.38M | 0.18% | 867,319 | – | – |
|
72
argenx
ARGX
$43.6B
| $6.71M | 0.16% | +15,600 | New | +$6.71M |
|
73
Allogene Therapeutics
ALLO
$251M
| $6.35M | 0.15% | +2,725,000 | New | +$6.35M |
|
74
Veru
VERU
$47.6M
| $5.94M | 0.14% | 7,063,277 +1,478,578 | +26% | +$1.24M |
|
75
KalVista Pharmaceuticals
KALV
$678M
| $5.89M | 0.14% | 500,000 | – | – |
|